DOSING

TAGRISSO offers convenient, once-daily dosing, with or without food¹

ONE TABLET ONCE A DAY

ONE TABLET ONCE A DAY

One 80-mg tablet, orally,
once a day

WITH OR WITHOUT

WITH OR WITHOUT

TAGRISSO tablets may be taken with or without food

TAGRISSO can be dissolved into water and swallowed or taken through an NG tube*

Alternate administration options

If the patient is unable to swallow the tablet, the tablet may first be dispersed in 50 mL of non-carbonated water
- It should be dropped in the water, without crushing, stirred until dispersed and immediately swallowed. An additional half a glass of water should be added to ensure that no residue remains and then immediately swallowed

If administration via nasogastric tube is required, the same process described for diluting in a cup should be followed but using volumes of 15 mL for the initial dispersion and 15 mL for the residue rinses

Dosing modifications

Some adverse reactions may require dose interruption or discontinuation¹

Target Organ	Adverse reaction*	Recommended dose modification
Pulmonary	ILD/Pneumonitis	Permanently discontinue TAGRISSO
Cardiac	QTc interval greater than 500 msec on at least 2 separate ECGs	Withhold TAGRISSO until QTc interval is less than 481 msec or recovery to baseline if baseline QTc is greater than or equal to 481 msec, then restart at a reduced dose (40 mg)
Cardiac	QTc interval prolongation with signs/symptoms of serious arrhythmia	Permanently discontinue TAGRISSO
Other	Grade 3 or higher adverse reaction	Withhold TAGRISSO for up to 3 weeks
	If Grade 3 or higher adverse reaction improves to Grade 0–2 after withholding of TAGRISSO for up to 3 weeks	TAGRISSO may be restarted at the same dose (80 mg) or a lower dose (40 mg)
	Grade 3 or higher adverse reaction that does not improve to Grade 0–2 after withholding for up to 3 weeks	Permanently discontinue TAGRISSO

1L Efficacy

1L Efficacy

Safety

Safety

Reference:
1. AstraZeneca Pharmaceuticals. TAGRISSO^® (osimertinib). Summary of Product Characteristics, 2018.